Search Site

Trends banner

Oracle shares up 35%

Huge AI contracts lead to the surge.

ADCB to raise $1.66bn

The rights issue aimed at boosting growth.

EGA H1 revenue $4.11bn

Net profit before GAC $445 million.

Borouge to pay $660m H1 dividend

Its net profit for H1 was $474 million.

TAQA secures $2.31bn loan

It will be utilized in a phased manner.

Sanofi 2022 net profit at $7.3bn

Sanofi's earnings per share rose by 17.1 percent to US$9 but Sanofi forecast low single-digit growth this year. (AFP)
  • Sanofi is aiming for US$10.9 billion in sales of Dupixent this year.
  • The company's net profit rose by eight percent in 2022.

PARIS, FRANCE – French pharmaceutical giant Sanofi forecast slower earnings growth for 2023 on Friday after profits jumped in 2022 on the back of popular eczema and asthma drug Dupixent.

The company’s net profit rose by eight percent to US$7.3 billion (6.7 billion euros) last year.

Its earnings per share, or profits divided by outstanding shares, rose by 17.1 percent to US$9 (8.26 euros), but Sanofi forecast “low single-digit” growth this year.

Sanofi shares fell following the announcement.

The company’s Dupixent treatment has been a huge success for Sanofi, raking in US$9 billion (8.3 billion euros) in sales last year.

“Dupixent and Vaccines continue to be our leading growth drivers,” Sanofi chief executive Paul Hudson said in a statement.

Sanofi is aiming for US$10.9 billion (10 billion euros) in sales of Dupixent this year.